Edgewise Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	23.45	17.63	11.03	2.21	1.3
Research & Development	90.91	54.03	32.19	14.98	8.62
Operating Expenses	114.36	71.66	43.22	17.19	9.92
Operating Income	-114.36	-71.66	-43.22	-17.19	-9.92
Other Expense / Income	-14.19	-4.02	-0.4	-0.07	-0.22
Pretax Income	-100.16	-67.64	-42.81	-17.12	-9.71
Net Income	-100.16	-67.64	-42.81	-17.12	-9.71
Shares Outstanding (Basic)	64	54	38	1	0
Shares Outstanding (Diluted)	64	54	38	1	0
Shares Change	18.90%	42.82%	4977.96%	95.63%	-
EPS (Basic)	-1.57	-1.26	-1.14	-23.17	-25.69
EPS (Diluted)	-1.57	-1.26	-1.14	-23.17	-25.69
Free Cash Flow	-97.69	-58.18	-34.18	-14.84	-9.35
Free Cash Flow Per Share	-1.53	-1.09	-0.91	-20.08	-24.75
EBITDA	-98.43	-67.1	-42.54	-16.94	-9.58
Depreciation & Amortization	1.73	0.54	0.27	0.19	0.12
EBIT	-100.16	-67.64	-42.81	-17.12	-9.71

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).